Status:
UNKNOWN
Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.
Lead Sponsor:
University of Sulaimani
Conditions:
Rheumatoid Arthritis
Inflammatory Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
Rheumatoid arthritis (RA) is an autoimmune, chronic inflammatory disease and TNF-alpha has been recognized as a triggering cytokine in the induction of joints inflammation and is involved in the patho...
Detailed Description
Rheumatologists in Iraq, including those in the Kurdistan Region, rely on the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) guidelines and publications due ...
Eligibility Criteria
Inclusion
- Meeting the ACR/EULAR 2010 criteria for rheumatoid arthritis (RA).
- Patients (or Legal Guardian, if applicable) who are willing to give informed consent for the study period-time follow up.
- Concomitant DMARDs
- Duration of treatment with TNF-alpha antagonists \<1 year, 1-5 years, \>5 years
Exclusion
- Tubercle Bacillus (TB)
- Hepatitis B, Hepatitis C
- Pregnancy and lactation
- Patients with heart failure.
- Previous or concurrent malignancies
Key Trial Info
Start Date :
March 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05379049
Start Date
March 1 2022
End Date
October 1 2022
Last Update
May 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hiwa Khidhir Saaed
Sulaymaniyah, Kurdistan Region, Iraq, 46001